CARLSMED, INC. — Form 10-Q
Filed August 5, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
Carlsmed adopted an amended Non-Employee Director Compensation Policy effective May 6, 2026, establishing annual retainers ($45K base director fee; $25K lead independent director; $10K–$20K committee chair fees), initial RSU grants of $300K per new director (vesting 1/3 annually over 3 years), and annual RSU grants of $150K per director (vesting in 1 year). Separately, on May 29, 2026, Customers Bank and Carlsmed amended their Loan and Security Agreement to increase permitted credit card indebtedness from an unspecified prior amount to $1,000,000 and credit card cash collateral accounts to $1,000,000 maximum.
Why this rating
Director compensation is routine governance; RSU policy standard for public companies. Credit card limit increase is operational/administrative. Neither materially alters business trajectory relative to $118.8M asset base.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.